TP53_PROF: a machine learning model to predict impact of missense mutations in TP53

被引:10
|
作者
Ben-Cohen, Gil [2 ]
Doffe, Flora [3 ]
Devir, Michal [2 ]
Leroy, Bernard [4 ]
Soussi, Thierry [4 ]
Rosenberg, Shai [1 ,5 ,6 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Jerusalem, Israel
[3] Univ Paris Saclay, Gif Sur Yvette, France
[4] Sorbonne Univ, Paris, France
[5] Hebrew Univ Jerusalem, Gaffin Ctr Neurooncol, Sharett Inst Oncol, Hadassah Med Ctr, Jerusalem, Israel
[6] Hebrew Univ Jerusalem, Wohl Inst Translat Med, Hadassah Med Ctr, Jerusalem, Israel
关键词
TP53; genetic counseling; Li-Fraumeni syndrome; precision medicine; personalized oncology; machine learning; DNA-BINDING COOPERATIVITY; P53; DATABASE; PROTEIN; OLIGOMERIZATION; RECOMMENDATIONS; CONFORMATION; REASSESSMENT; INHIBITION; LANDSCAPE;
D O I
10.1093/bib/bbab524
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Correctly identifying the true driver mutations in a patient's tumor is a major challenge in precision oncology. Most efforts address frequent mutations, leaving medium- and low-frequency variants mostly unaddressed. For TP53, this identification is crucial for both somatic and germline mutations, with the latter associated with the Li-Fraumeni syndrome (LFS), a multiorgan cancer predisposition. We present TP53_PROF (prediction of functionality), a gene specific machine learning model to predict the functional consequences of every possible missense mutation in TP53, integrating human cell- and yeast-based functional assays scores along with computational scores. Variants were labeled for the training set using well-defined criteria of prevalence in four cancer genomics databases. The model's predictions provided accuracy of 96.5%. They were validated experimentally, and were compared to population data, LFS datasets, ClinVar annotations and to TCGA survival data. Very high accuracy was shown through all methods of validation. TP53_PROF allows accurate classification of TP53 missense mutations applicable for clinical practice. Our gene specific approach integrated machine learning, highly reliable features and biological knowledge, to create an unprecedented, thoroughly validated and clinically oriented classification model. This approach currently addresses TP53 mutations and will be applied in the future to other important cancer genes.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] TP53 mutations predict response to cetuximab
    Mandy Aujla
    Nature Reviews Clinical Oncology, 2009, 6 (7) : 373 - 373
  • [2] A quantitative model to predict pathogenicity of missense variants in the TP53 gene
    Fortuno, Cristina
    Cipponi, Arcadi
    Ballinger, Mandy L.
    Tavtigian, Sean, V
    Olivier, Magali
    Ruparel, Vatsal
    Haupt, Ygal
    Haupt, Sue
    Tucker, Kathy
    Spurdle, Amanda B.
    Thomas, David M.
    James, Paul A.
    HUMAN MUTATION, 2019, 40 (06) : 788 - 800
  • [3] Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations
    Soussi, T
    Kato, S
    Levy, PP
    Ishioka, C
    HUMAN MUTATION, 2005, 25 (01) : 6 - 17
  • [4] TP53 or Not TP53: That Is the Question
    Green, Steven D.
    Zeidner, Joshua F.
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5235 - 5237
  • [5] Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
    Li, Xuerui
    Chen, Xiaoqing
    Wen, Lingzhu
    Wang, Yulei
    Chen, Bo
    Xue, Yunlian
    Guo, Liping
    Liao, Ning
    THORACIC CANCER, 2020, 11 (07) : 1861 - 1868
  • [6] Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
    Tam, Benjamin
    Sinha, Siddharth
    Qin, Zixin
    Wang, San Ming
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [7] The impact of TP53 and RAS mutations on cerebellar glioblastomas
    Milinkovic, Vedrana P.
    Gazibara, Milica K. Skender
    Gacic, Emilija M. Manojlovic
    Gazibara, Tatjana M.
    Tanic, Nikola T.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2014, 97 (02) : 202 - 207
  • [8] TP53 missense mutations associate with different metabolic pathways.
    Kelemen, Linda E.
    Brenton, James D.
    Bowtell, David D.
    Fridley, Brooke L.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 44 - 44
  • [9] Drastic Effect of Germline TP53 Missense Mutations in LiFraumeni Patients
    Zerdoumi, Yasmine
    Aury-Landas, Juliette
    Bonaiti-Pellie, Catherine
    Derambure, Celine
    Sesbouee, Richard
    Renaux-Petel, Mariette
    Frebourg, Thierry
    Bougeard, Gaelle
    Flaman, Jean-Michel
    HUMAN MUTATION, 2013, 34 (03) : 453 - 461
  • [10] TP53 mutations in myelodysplastic syndrome
    Misawa, S
    Horiike, S
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 417 - 422